Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936325 | 0.86 | MAOA (0.56) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL6991403 | 0.84 | MAOA (0.54) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL7003510 | 0.84 | MAOA (0.54) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL4247907 | 0.84 | MAOA (0.54) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL7830030 | 0.79 | CYP2A6 (0.59) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL3467047 | 0.76 | CYP3A4 (0.59) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL5488820 | 0.76 | CYP2A6 (0.59) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL4235603 | 0.76 | CYP3A4 (0.59) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL11392904 | 0.76 | HTT (0.51) | MAOACYP2A6CYP3A4HSD17B10ACHE | |
| SCHEMBL10405182 | 0.76 | MAOA (0.44) | MAOACYP2A6CYP3A4HSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012164484-A1 | ADENOSINE OR DEOXYADENOSINE DERIVATIVES MODIFIED AT POSITION 8 AND A METHOD OF SYNTHESIS THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2012-12-06 | — | — | WO | disclosed |
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1133498-A2 | AMINO-AND MERCURIO-SUBSTITUTED 4', 5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-2000031081-A2 | AMINO- AND MERCURIO-SUBSTITUTED 4',5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF | BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | MAOA 2213/4885CYP2A6 1441/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.